Trial Profile
Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SUNSTAR
- 12 Sep 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2024.
- 12 Sep 2023 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2024.
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.